Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44
- PMID: 23153439
- DOI: 10.1016/j.vaccine.2012.10.110
Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44
Comment in
-
Cost-effectiveness of adult pneumococcal vaccination: response to Grabenstein et al.Vaccine. 2013 Apr 19;31(17):2109. doi: 10.1016/j.vaccine.2013.01.008. Epub 2013 Jan 11. Vaccine. 2013. PMID: 23318148 No abstract available.
Comment on
-
Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years.Vaccine. 2012 Aug 3;30(36):5437-44. doi: 10.1016/j.vaccine.2012.05.076. Epub 2012 Jun 20. Vaccine. 2012. PMID: 22728289
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical